Mahmoud A. Elshenawy

Mahmoud A. Elshenawy

Auto-generated profile, based on publicly available information

Mahmoud A. Elshenawy

Medical Oncology Department, Cancer Center of Excellence, King Faisal Specialist Hospital and Research Centre

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 November 2022 in Cureus
Verified
Journal Article
Open access
HAHamed Alhusaini
Hamed Alhusaini
MEMahmoud A Elshenawy
Mahmoud A Elshenawy
ABAhmed Badran
Ahmed Badran
AEAyman Elshentenawy
Ayman Elshentenawy
AMAhmed Mohieldin
Ahmed Mohieldin
HSHussein Soudy
Hussein Soudy
Objectives: Ovarian granulosa cell tumour is rare. This study aims to report the clinical characteristics and long-term outcomes of adult-type ovarian granulosa cell tumour (AOGCT) at King Faisal Specialist Hospital and Research Centre (KFSH&RC) and to determine the prognostic factors affecting relapse and survival. Methods: We retrospectively reviewed patients with AOGCT, from 1988 to 2014, who were treated at our institution. Baseline characteristics, pathological findings, and outcomes were analysed and reported. Results: Sixty-one patients with AOGCT were identified with a median age of 49 years. Median follow-up was 5.0 years (range 2.1-8.2 years). 74% of patients were FIGO (International Federation of Gynecology and Obstetrics) stage I, whereas 7% were stage II, 5% were stage III, and unknown in 14% of the cases. The most common presenting symptoms included abdominal pain (43%) and vaginal bleeding (43%). The majority of patients (38 patients, 62%) were treated with total abdominal hysterectomy and bilateral salpingo-oophorectomy. Five (8%) patients received adjuvant chemotherapy. Sixteen patients (26%) relapsed with a median time to relapse of 5.5 years (0.7-8.1 years). Half of the recurrences (eight patients, 50%) occurred after five years of diagnosis. Five-year overall survival and disease-free survival (DFS) were 93% and 84%, respectively. Factors associated with a high risk of recurrence were the presence of ascites (p=0.000) and elevated preoperative CA 125 level (p=0.048). The overall survival was significantly influenced by the menopausal status (premenopausal 100% vs. postmenopausal 84%; p=0.02), preoperative CA 125 (normal 100% vs. elevated 64%; p=0.005), ascites (present 33% vs. absent 100%; p=0.000), and age (<55 years 100% vs. ≥ 55 years 77%; p= 0.002). Conclusion: This study confirms a good outcome for patients with AOGCT. They require long-term follow-up as late recurrences can occur many years post definitive therapy. The presence of ascites and elevated preoperative CA 125 levels were associated with a higher risk of recurrence and poor prognosis. Outcomes appear unaffected by fertility-sparing surgery or adjuvant chemotherapy.

12 February 2021 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
TATaher AL-Tweigeri
Taher AL-Tweigeri
MEMahmoud Elshenawy
Mahmoud Elshenawy
ABAhmed Badran
Ahmed Badran
AOAyman Omar
Ayman Omar
KSKausar Suleman
Kausar Suleman
ASAdher Al Sayed
Adher Al Sayed
Purpose. This study was designed to examine the relationship between breast cancer molecular subtypes and pathological response to neoadjuvant chemotherapy (NAC)±trastuzumab, in locally advanced breast cancer (LABC). Methods. Female patients with LABC (T2T4, N0N2, and M0) who received neoadjuvant chemotherapy+trastuzumab if HER2+ subtype, followed by surgery and radiotherapy±hormonal therapy, were identified. The primary endpoint was pathologic complete response (pCR) in the breast and axilla (ypT0/ypN0), with final analysis on disease-free survival (DFS) and overall survival (OS). Results. Six hundred eighty-one patients with a median age of 44 years, premenopausal: 70, median tumour size: 7.0cm (range 411cm), stage II B: 27 and III A/III B: 73, ER+/HER2: 40.8, ER/HER2: 23, ER+/HER2+: 17.7, and ER/HER2+: 18.5. Overall pCR (ypT0/ypN0) was 23. The pCR rates based on molecular subtypes were ER+/HER2: 9; ER+/HER2+: 29; ER/HER2: 31; and ER/HER2+: 37. At median follow-up of 61 months, ER+/HER2+ and ER+/HER2 subtypes had the best 5-year DFS and OS; meanwhile, ER/HER2+ and ER/HER2 subtypes had the worst. Conclusion. Women with ER+/HER2 disease are the least likely to achieve pCR, with the highest rates in HER2+ and triple-negative subgroups. Degree of response is associated with OS; despite the comparatively higher likelihood of achieving pCR in ER/HER2+ and triple-negative, these subgroups experience a survival detriment. We are consistent with the published data that patients who attain the pathological complete response defined as ypT0/ypN0 have improved outcomes.

22 May 2024 in Molecular and Clinical Oncology
Verified
Journal Article
Open access
PDF file
HAHamed Alhusaini
Hamed Alhusaini
ABAhmed Badran
Ahmed Badran
AJAmal Al Juhani
Amal Al Juhani
BABader Alshamsan
Bader Alshamsan
YAYasamiyan Alsagaih
Yasamiyan Alsagaih
MEMahmoud A. Elshenawy
Mahmoud A. Elshenawy
Low‑grade serous ovarian cancer (LGSOC) is a very rare histological subtype of serous ovarian cancer, representing ~2% of all epithelial ovarian cancer cases. LGSOC has a better prognosis but a lower response rate to chemotherapy in comparison to high‑grade serous ovarian carcinoma (HGSOC). The present study is a retrospective review of the medical records of all patients with histologically proven LGSOC diagnosed and treated in a single institute between January 2003 and December 2019. A total of 23 patients diagnosed with LGSOC and treated at King Faisal Specialist Hospital and Research Center (Riyadh, Saudi Arabia) were identified. The median age at diagnosis was 45.5 years (range, 26‑66 years) and the median body mass index was 26.1 (range, 18‑43). A total of 21 patients (91.3%) had de novo LGSOC, whereas only 2 patients (8.7%) had LGSOC that had transformed from serous borderline ovarian tumors and recurred. A total of 8 patients (34.8%) were diagnosed with International Federation of Gynecology and Obstetrics stage IV, whereas 3 (13.0%), 3 (13.0%) and 9 (39.1%) were diagnosed with stages I, II and III, respectively. In addition, 10 (43.5%), 5 (21.7%), and 3 (13.0%) patients had complete response, stable disease and partial response statuses after first‑line therapy, respectively. At a median follow‑up time of 34 months [95% confidence interval (CI), 25.32‑42.69], the median progression‑free survival (PFS) time was 75.2 months (95% CI, 17.35‑133.05) and the median overall survival (OS) time was not reached. In conclusion, LGSOC exhibited better PFS and OS times than HGSOC as compared with data from the literature, and there is the option for systemic treatment (chemotherapy or hormonal therapy). Optimal cytoreduction showed numerically higher, but non‑significant, PFS and OS times compared with suboptimal debulking; however, the optimal systemic chemotherapy or hormonal treatment remains controversial.

8 July 2020 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
MEMahmoud A. Elshenawy
Mahmoud A. Elshenawy
ABAhmed Badran
Ahmed Badran
AAAli Aljubran
Ali Aljubran
AAAhmed Alzahrani
Ahmed Alzahrani
MRM. Shahzad Rauf
M. Shahzad Rauf
SBShouki Bazarbashi
Shouki Bazarbashi
Background: Surgical resection of metastatic disease in patients with initially non-resectable colorectal cancer (CRC) has improved overall survival. Intensified chemotherapy regimens have increased the probability of converting unresectable metastasis to resectable. Here, we report the result of combining intensive chemotherapy (triplet) and surgical resection of metastatic lesions in patients with metastatic CRC. Patients and methods: Patients with unresectable metastatic CRC were enrolled in phase I/II trial of triplet chemotherapy consisting of capecitabine, oxaliplatin, irinotecan, and bevacizumab. Patients were given 5–8 cycles induction chemotherapy of the above regimen followed by maintenance capecitabine and bevacizumab until disease progression, unacceptable toxicity, or patient request. All patients were assessed at a multidisciplinary conference for possible surgical resection of their metastatic disease at the time of inclusion in the trial and 2 monthly intervals thereafter. Patients who underwent R0 resection of their metastatic disease received adjuvant oxaliplatin and capecitabine to complete a total of 6 months of chemotherapy. Results: Fifty-three patients were enrolled. The median age was 52 years (range 23–74), 29 (55%) were males, ECOG PS 0-1 was 13 (66%), 11 (42%) had a right-sided tumor, 29 (55%) had resection of their primary tumor, 22 (42%) had a single metastatic site, and 8 (15.1%) had a liver-limited disease. Thirteen patients (24.5%) underwent surgical resection of residual metastatic disease +/− the primary tumor with 10 (18.9%) of them were R0. The surgical group had a higher incidence of males compared to the non-surgical group (69.3% vs 47.2%, p = 0.2), equal performance status, lower median number of metastatic sites (1 vs 2, p = 0.09), higher mutant Kras (53.8% vs 34.2%, p = 0.3), and higher response rate (84.6% vs 56.2%, p = 0.3). With a median follow-up duration of 89 months, the median PFS for the whole group was 16.1 months [95% confidence interval (CI) 9.1–20] and the median OS was 28.2 months (95% CI 22.5–53.3). The median PFS for the surgery group was 18.9 months (95% CI 12.6–not reached) compared to 9.6 months (95% CI 7.0–18.3) for the non-surgical group, log-rank p = 0.0165. The median OS for both groups was not reached (95% CI 53.3–not reached) and 23.2 months (95% CI 17.0–28.4) respectively, log-rank p = 0.0006. Five-year PFS and OS for the surgery group were 46.2% and 67.6% respectively. Conclusions: Patients with unresectable metastatic CRC and fit for triplet chemotherapy should have the benefit of combining this intensified regimen and surgical resection of their metastatic disease if possible. Trial registration: Clinicaltrials.gov, NCT01311050, registered March 6, 2011, retrospectively registered.

1 February 2019 in Research in Oncology
Verified
Journal Article
Closed access
PDF file
MEMahmoud A. Elshenawy
Mahmoud A. Elshenawy
ABAhmed Badran
Ahmed Badran
AEAyman Elshentenawy
Ayman Elshentenawy
AEAbdelmonem Eldali
Abdelmonem Eldali
MMMuhammad Memon
Muhammad Memon
Background: Giant-cell tumor of bone (GCTB) is a locally aggressive tumor which metastasizes infrequently to the lungs. The standard treatment of GCTB was surgery until the approval of denosumab. Aim: To describe the outcome of treatment of this rare tumor and to determine factors that influence survival. Methods: Retrospective review of the medical records of GCTB patients treated at our institution. Collected data includes: clinicopathological data, treatment modalities and possible prognostic factors. Results: Forty-two patients were identified between May 2008 and November 2017. Their median age was 31 years, and the majority (62%) were females. The commonest primary sites were the upper and lower limbs (50% and 43%, respectively). Eight (19%) patients initially presented with lung metastases. Thirteen (31%) patients received denosumab as first line treatment before surgery and 12 of them underwent surgery post-denosumab. Denosumab was given after recurrence in 12 (29%) patients [8 (19%) with lung metastasis and 4 (10%) with localized disease]. The objective response rate to denosumab after recurrence was 50%. Four (10%) patients achieved complete response and 2 (5%) partial response. After a median follow up of 4.7 years, 6 (14%) patients had local recurrence and 8 (19%) had lung metastasis with no recorded deaths. The 5-year progression-free survival rate was 61%. Conclusion: Denosumab is effective and tolerable in the management of GCTB preoperatively in localized disease to facilitate surgery and in the management of metastatic disease. Multi-institutional prospective studies are needed for further assessment.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
MIMichael Iskedjian
Michael Iskedjian
EVEdward Bentz De Vol
Edward Bentz De Vol
MEMahmoud Elshenawy
Mahmoud Elshenawy
SBShouki Bazarbashi
Shouki Bazarbashi
PURPOSE: Health utilities (HUs) are quantitative measures of quality of life that are used to derive outcomes such as quality-adjusted life years in cost-effectiveness analyses. In the Kingdom of Saudi Arabia, there are no HUs for cancer. This study aimed to generate HU estimates for various health states associated with cancer in the Kingdom of Saudi Arabia.METHODS: Adult citizens of the Kingdom of Saudi Arabia, patients with cancer, and patients without cancer were recruited to participate in an online version of the Time Trade-Off (TTO) survey, a direct method that asks participants to indicate the amount of time they are willing to trade off in return for full health. The time horizon was 10 years. Patients were surveyed on their own health state; patients without cancer were presented with a scenario describing stage III colon cancer and were asked to act as proxies.RESULTS: Mean HU score was 0.398 (n = 398), 0.315 for patients with cancer (n = 199), and 0.482 for patients without cancer (n = 199). Among patients, the largest subgroup with colorectal cancer (n = 105), had a mean HU of 0.296; the subgroup with the lowest mean HU was patients with hepatocellular cancer (n = 3; 0.047), and the subgroup with the highest mean HU was patients with cholangiocarcinoma (n = 5; 0.508). Overall, the initial stage I subgroup (n = 7) had a mean HU of 0.456; initial stage II (n = 25), 0.240; stage II (n = 67), 0.319; and initial stage IV (n = 77), 0.320.CONCLUSION: To our knowledge, this is the first study of this size to elicit HU scores for cancer in the Kingdom of Saudi Arabia. Patients may have had clinically worse disease than the patients in the scenario that was presented to patients without cancer. Further analyses are warranted for specific types of cancer. These HUs can in turn be applied in cost-utility analyses.